CureVac N.V. (CVAC)
After hours:
| Previous Close | 2.3100 |
| Open | 2.3200 |
| Bid | 2.3100 x 600 |
| Ask | 2.3400 x 400 |
| Day's Range | 2.2800 - 2.4200 |
| 52 Week Range | 2.2150 - 12.3600 |
| Volume | |
| Avg. Volume | 794,914 |
| Market Cap | 521.743M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5700 |
| Earnings Date | May 21, 2024 - May 27, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.63 |
Insider MonkeyCureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript
CureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript April 24, 2024 CureVac N.V. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to the CureVac Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call. […]
ACCESSWIRECureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA) with Federal Republic of Germany, after consultation ...
- ACCESSWIRE
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic ...
